Wai Yuen Tong Medicine Holdings Limited (0897.HK)
HKD 0.21
(-0.48%)
HKD 0.21
(-0.48%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 276.2 Million HKD | -73.25% |
| 2022 | 1.03 Billion HKD | -0.81% |
| 2021 | 1.04 Billion HKD | 15.6% |
| 2020 | 900.44 Million HKD | -21.54% |
| 2019 | 1.14 Billion HKD | 85.12% |
| 2018 | 619.93 Million HKD | -6.39% |
| 2017 | 662.22 Million HKD | -4.99% |
| 2016 | 697.01 Million HKD | 20.23% |
| 2015 | 579.75 Million HKD | 65.23% |
| 2014 | 350.87 Million HKD | 85.24% |
| 2013 | 189.41 Million HKD | 372.29% |
| 2012 | 40.1 Million HKD | -43.6% |
| 2011 | 71.11 Million HKD | -16.77% |
| 2010 | 85.43 Million HKD | 134.08% |
| 2009 | 36.5 Million HKD | -22.64% |
| 2008 | 47.18 Million HKD | -78.38% |
| 2007 | 218.21 Million HKD | 397.32% |
| 2006 | 43.87 Million HKD | -53.55% |
| 2005 | 94.46 Million HKD | -26.79% |
| 2004 | 129.03 Million HKD | 104.96% |
| 2003 | 62.95 Million HKD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 877.7 Million HKD | 0.0% |
| 2023 FY | 276.2 Million HKD | -73.25% |
| 2023 Q4 | 276.2 Million HKD | 0.0% |
| 2022 Q2 | 1.21 Billion HKD | 0.0% |
| 2022 FY | 1.03 Billion HKD | -0.81% |
| 2022 Q4 | 1.03 Billion HKD | 0.0% |
| 2021 Q4 | 1.04 Billion HKD | 0.0% |
| 2021 Q2 | 899.24 Million HKD | 0.0% |
| 2021 FY | 1.04 Billion HKD | 15.6% |
| 2020 Q4 | 900.44 Million HKD | 0.0% |
| 2020 FY | 900.44 Million HKD | -21.54% |
| 2020 Q2 | 1.1 Billion HKD | 0.0% |
| 2019 FY | 1.14 Billion HKD | 85.12% |
| 2019 Q2 | 484.32 Million HKD | 0.0% |
| 2019 Q4 | 1.14 Billion HKD | 0.0% |
| 2018 Q4 | 619.93 Million HKD | 0.0% |
| 2018 Q2 | 642.33 Million HKD | 0.0% |
| 2018 FY | 619.93 Million HKD | -6.39% |
| 2017 FY | 662.22 Million HKD | -4.99% |
| 2017 Q2 | 679.62 Million HKD | 0.0% |
| 2017 Q4 | 662.22 Million HKD | 0.0% |
| 2016 Q4 | 697.01 Million HKD | 0.0% |
| 2016 Q2 | 716.25 Million HKD | 0.0% |
| 2016 FY | 697.01 Million HKD | 20.23% |
| 2015 Q4 | 579.75 Million HKD | 0.0% |
| 2015 Q2 | 363.18 Million HKD | 0.0% |
| 2015 FY | 579.75 Million HKD | 65.23% |
| 2014 Q3 | 350.87 Million HKD | 92.18% |
| 2014 FY | 350.87 Million HKD | 85.24% |
| 2014 Q1 | 182.57 Million HKD | -3.61% |
| 2014 Q4 | 350.87 Million HKD | 0.0% |
| 2014 Q2 | 182.57 Million HKD | 0.0% |
| 2013 Q1 | 228.2 Million HKD | 469.03% |
| 2013 Q4 | 189.41 Million HKD | 0.0% |
| 2013 FY | 189.41 Million HKD | 372.29% |
| 2013 Q3 | 189.41 Million HKD | -17.0% |
| 2013 Q2 | 228.2 Million HKD | 0.0% |
| 2012 Q1 | 63.94 Million HKD | -10.07% |
| 2012 Q4 | 40.1 Million HKD | 0.0% |
| 2012 Q3 | 40.1 Million HKD | -37.28% |
| 2012 FY | 40.1 Million HKD | -43.6% |
| 2012 Q2 | 63.94 Million HKD | 0.0% |
| 2011 Q4 | 71.11 Million HKD | 0.0% |
| 2011 FY | 71.11 Million HKD | -16.77% |
| 2011 Q2 | 78.27 Million HKD | 0.0% |
| 2010 FY | 85.43 Million HKD | 134.08% |
| 2010 Q2 | 31.7 Million HKD | 0.0% |
| 2010 Q4 | 85.43 Million HKD | 0.0% |
| 2009 Q4 | 36.5 Million HKD | 0.0% |
| 2009 FY | 36.5 Million HKD | -22.64% |
| 2008 FY | 47.18 Million HKD | -78.38% |
| 2007 FY | 218.21 Million HKD | 397.32% |
| 2006 FY | 43.87 Million HKD | -53.55% |
| 2005 FY | 94.46 Million HKD | -26.79% |
| 2004 FY | 129.03 Million HKD | 104.96% |
| 2003 FY | 62.95 Million HKD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -13223.692% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 72.102% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | -135.818% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | -291.019% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -666.015% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -2057.644% |
| PuraPharm Corporation Limited | 81.09 Million HKD | -240.597% |
| SSY Group Limited | 1.94 Billion HKD | 85.818% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -530.594% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 53.36% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 98.338% |